Biochemical Markers of Metabolic Syndrome: From Lipid Profiles to Inflammatory Cytokines

Background: Metabolic syndrome (MetS) is a multifactorial disorder characterized by a cluster of interconnected metabolic abnormalities including central obesity, dyslipidemia, insulin resistance, and hypertension, which collectively elevate the risk of type 2 diabetes and cardiovascular disease. The identification of robust biochemical markers is essential for early diagnosis, risk stratification, and therapeutic monitoring. Recent advances in molecular profiling have expanded the panel of metabolic and inflammatory biomarkers implicated in the pathophysiology of MetS. Methods and Results: This review provides a comprehensive overview of key biochemical markers associated with MetS, spanning traditional lipid metrics and emerging cytokine signatures. Elevated levels of triglycerides, low HDL cholesterol, and small dense LDL particles are hallmark features of MetS-related dyslipidemia. Concurrently, insulin resistance correlates with elevated fasting glucose and increased HOMA-IR index. Beyond these classical parameters, a pro-inflammatory milieu characterized by elevated C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and adipokines such as leptin and resistin reflects systemic immune activation and metabolic dysregulation. Biomarkers of oxidative stress (e.g., malondialdehyde, oxidized LDL) and endothelial dysfunction (e.g., ICAM-1, VCAM-1) further delineate cardiovascular risk in MetS patients. Proteomic and metabolomic analyses have identified novel candidate markers including branched-chain amino acids (BCAAs), acylcarnitines, and ceramides that correlate with disease severity and progression. These biochemical signatures not only enhance mechanistic understanding but also offer potential for precision medicine approaches. Conclusion: The integration of classical and emerging biochemical markers provides a multidimensional view of the metabolic and inflammatory landscape in MetS.